<p><strong><em>本研究在同行評審期刊上的發表預計將解鎖 500 萬美元的合同里程碑付款</em></strong></p>
<p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;），一家跨國表觀遺傳學公司，宣佈提交一篇臨牀手稿進行同行評審，報告其 Nu.Q® Vet Feline 原型檢測在檢測貓淋巴瘤（該物種中最常見的癌症）方面的高準確性。該檢測在 97% 的特異性下檢測到了 86% 的貓淋巴瘤。這一突破標誌着我們預計將開發出全球首個簡單、經濟的基於血液的貓癌症液體活檢測試，這在獸醫學中是一個重要的未滿足需求。</p>
<p><strong>安娜麗莎·卡納萊博士，</strong> Volition 的首席作者評論道：</p>
<p>&#34;貓腫瘤學缺乏腫瘤生物標誌物，因此貓的癌症早期診斷一直非常困難。</p>
<p>&#34;基於我們之前對犬淋巴瘤的研究，本研究旨在強調循環核小體作為生物標誌物的實用性，以區分健康與中大型細胞淋巴瘤的貓。</p>
<p>&#34;中大型細胞淋巴瘤的貓的核小體水平顯著高於健康對照，表明 H3.1-核小體作為篩查貓中大型細胞淋巴瘤的新有用生物標誌物的潛在作用。&#34;</p>
<p><strong>蓋爾·福特爾，</strong> Volition 首席商業官評論道：</p>
<p>&#34;這代表了 Volition 的巨大商業機會：</p>
<ul>
<li>本研究在同行評審期刊上的發表預計將解鎖 500 萬美元的合同里程碑付款；並且</li>
<li>我們計劃在這個龐大且快速增長的市場中產生持續的收入，我們的技術滿足了未滿足的需求。</li>
</ul>
<p>&#34;我們的使命是使癌症篩查成為每隻寵物年度健康檢查的常規部分，在成功國際推廣我們的犬癌症檢測後，我們現在已經證明我們的技術對貓也有效。</p>
<p>&#34;我們期待完成產品開發，並通過我們的分銷網絡（包括參考實驗室和即時檢測平台）使 Nu.Q® Vet Feline 測試可用。</p>
<p>&#34;Nu.Q® Vet Canine 測試已經在 20 多個國家可用，我們相信增加一個貓的等效測試可能會使我們在伴侶動物領域的總可尋址市場翻倍。&#34;</p>
<p>Nu.Q® Vet Feline 測試切入了一個重要的、快速增長的市場：</p>
<ul>
<li><strong>龐大的人口：</strong> 美國僅有約 <strong>7380 萬隻寵物貓</strong>。</li>
<li><strong>高風險：</strong> 估計約 <strong>五分之一的貓</strong> 在其一生中會患上癌症。貓淋巴瘤是該物種中最常見的癌症，是 Nu.Q®檢測的主要目標。</li>
<li><strong>“老年” 羣體：</strong> 超過 <strong>25% 的美國貓</strong> 被認為是老年貓（年齡 8 歲以上），這為美國超過 1800 萬隻寵物提供了每年定期篩查的機會。</li>
<li><strong>市場增長：</strong> 北美獸醫腫瘤學市場預計到 2025 年將達到 <strong>17.7 億美元</strong>，其中貓的細分市場預計將以比犬類細分市場更快的複合年增長率增長，原因是主人意識的提高和對貓特定治療的關注增加。&#34;</li>
</ul>
<p>該論文將在接下來的幾天內在預印本服務上發佈。</p>
<ol>
<li>數據存檔</li>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 第 6 版. Elsevier Health Sciences; 2019。</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8</li>
<li>C. Dolan 等，BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-x</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6</li>
<li><em>AVMA 寵物擁有源書</em> <em>(2025)</em> 6 <em>APPA 全國寵物主人調查 (2025)</em></li>
<li>貓會得癌症嗎？瞭解貓淋巴瘤和 SCC 等貓癌症。Imprimed</li>
<li>數據存檔，Volition TAM 模型</li>
<li>面向醫療保健：獸醫腫瘤學市場洞察（2025 年 10 月）</li>
</ol>
<p><strong>關於 Volition</strong></p>
<p>關於 Volition：Volition 是一家專注於推進表觀遺傳學科學的跨國公司。Volition 致力於通過早期檢測以及疾病和治療監測來拯救生命並改善人類和動物在重大疾病中的預後。</p>
<p>通過其子公司，Volition 正在開發和商業化簡單、易用、經濟的血液檢測，以幫助檢測和監測一系列疾病，包括一些癌症和與 NETosis 相關的疾病，如膿毒症。早期檢測和監測不僅有潛力延長患者的生命，還能改善他們的生活質量。</p>
<p>Volition 的研究和開發活動集中在比利時，在美國設有創新實驗室和辦公室，並在倫敦設有辦公室。</p>
<p>Volition 網站上的內容不被視為本文件的一部分，也不應被視為本文件的一部分。該網站地址僅作為非活動文本引用包含在本文件中。</p>
<p><strong>媒體諮詢：</strong> Louise Batchelor, Volition, [email protected], +44 (0) 7557 774620</p>
<p><strong>安全港聲明</strong></p>
<p>本新聞稿或相關視頻或鏈接中的聲明可能是根據《1933 年證券法》第 27A 條和《1934 年證券交易法》第 21E 條的定義的 “前瞻性聲明”，涉及可能導致實際結果與前瞻性聲明中預期或預測的結果存在重大差異的風險和不確定性。諸如 “預計”、“預期”、“打算”、“計劃”、“目標”、“旨在”、“目標”、“相信”、“尋求”、“估計”、“優化”、“潛在”、“目標”、“建議”、“可能”、“將”、“應該”、“或許”、“會” 等類似表達識別前瞻性聲明。這些前瞻性聲明涉及的主題包括，Volition 對收入機會、里程碑付款和增長的預期，Volition 基於血液的診斷、預後和疾病監測測試的有效性和可用性，Volition 開發和成功商業化這些測試平台以早期檢測癌症和其他疾病的能力，以及作為這些疾病的診斷、預後或疾病監測工具的能力，Volition 對未來出版物的預期，Volition 在與第三方為其產品達成許可和/或分銷協議方面的成功，以及 Volition 對這些協議條款的預期。由於眾多風險和不確定性，Volition 的實際結果可能與這些前瞻性聲明中所指示的結果存在重大差異，包括但不限於測試有效性研究的結果。例如，如果 Volition 未能開發和商業化診斷、預後或疾病監測產品，可能無法執行其運營計劃。其他風險和不確定性包括 Volition 未能獲得必要的監管許可或批准以分銷和營銷未來產品；市場未能接受 Volition 開發管道中的產品或 Volition 可能開發的任何其他診斷、預後或疾病監測產品；Volition 未能獲得足夠的知識產權保護；Volition 將面臨激烈的競爭，且由於診斷和疾病監測市場的高度競爭性及其快速的技術變革，Volition 計劃中的產品可能會變得過時；國內和國際經濟的下滑；以及其他風險，包括在 Volition 最近的 10-K 表格年度報告和 10-Q 表格季度報告中識別的風險，以及 Volition 向證券交易委員會提交的其他文件。這些聲明基於當前的預期、估計和關於 Volition 業務的預測，部分基於管理層做出的假設。這些聲明並不保證未來的表現，並涉及難以預測的風險、不確定性和假設。前瞻性聲明是在本發佈之日作出的，除法律要求外，Volition 不承擔更新其前瞻性聲明以反映未來事件或情況的義務。</p>
<p>rNuQ™、Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的標誌是 VolitionRx Limited 及其子公司的商標和/或服務標誌。本新聞稿或相關視頻或鏈接中提到的所有其他商標、服務標誌和商號均為其各自所有者的財產。此外，除非另有説明，所有提及的 “$” 均指美國法定貨幣。</p>
<p>圖片 - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg</p>
<p>來源：VolitionRx Limited</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA2Jk5ld3NJdGVtSWQ9TE41MjU5NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDYwODE3UFJfTkVXU19VU1BSX19fX19MTjUyNTk3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA2Jk5ld3NJdGVtSWQ9TE41MjU5NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDYwODE3UFJfTkVXU19VU1BSX19fX19MTjUyNTk3"/></p>

VNRX

<p>VolitionRx Limited 已提交一份臨牀手稿以供同行評審，內容涉及其 Nu.Q® Vet Feline 原型檢測，能夠以 97% 的特異性準確檢測貓的淋巴瘤。這一突破可能解鎖 500 萬美元的里程碑付款，並滿足獸醫學中的重要需求。該公司旨在使寵物的癌症篩查成為常規，預計貓科測試將使其市場潛力翻倍。預計到 2025 年，北美獸醫腫瘤學市場將達到 17.7 億美元，貓科治療的意識和關注度不斷提高，推動了市場增長</p>

<p><strong><em>The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment</em></strong></p>
<div class="lb-trans"><p><strong><em>本研究在同行評審期刊上的發表預計將解鎖 500 萬美元的合同里程碑付款</em></strong></p>
</div><p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2. At 97% specificity the assay detected 86% of feline lymphomas1. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;），一家跨國表觀遺傳學公司，宣佈提交一篇臨牀手稿進行同行評審，報告其 Nu.Q® Vet Feline 原型檢測在檢測貓淋巴瘤（該物種中最常見的癌症）方面的高準確性。該檢測在 97% 的特異性下檢測到了 86% 的貓淋巴瘤。這一突破標誌着我們預計將開發出全球首個簡單、經濟的基於血液的貓癌症液體活檢測試，這在獸醫學中是一個重要的未滿足需求。</p>
</div><p><strong>Dr Annalisa Canale,</strong> Volition and first author on the paper commented:</p>
<div class="lb-trans"><p><strong>安娜麗莎·卡納萊博士，</strong> Volition 的首席作者評論道：</p>
</div><p>&#34;Feline oncology lacks tumor biomarkers and so cancer in cats have been notoriously difficult to diagnose early.</p>
<div class="lb-trans"><p>&#34;貓腫瘤學缺乏腫瘤生物標誌物，因此貓的癌症早期診斷一直非常困難。</p>
</div><p>&#34;Building on our prior findings for canine lymphoma3-5, this study aimed to highlight the utility of circulating nucleosomes as biomarker to differentiate healthy vs intermediate-large cell lymphoma in cats.</p>
<div class="lb-trans"><p>&#34;基於我們之前對犬淋巴瘤的研究，本研究旨在強調循環核小體作為生物標誌物的實用性，以區分健康與中大型細胞淋巴瘤的貓。</p>
</div><p>&#34;Nucleosome levels were significantly higher in cats with intermediate-large cell lymphoma compared to healthy controls indicating the potential role of H3.1-nucleosomes as a new useful biomarker for screening intermediate-large cell lymphoma in cats.&#34;</p>
<div class="lb-trans"><p>&#34;中大型細胞淋巴瘤的貓的核小體水平顯著高於健康對照，表明 H3.1-核小體作為篩查貓中大型細胞淋巴瘤的新有用生物標誌物的潛在作用。&#34;</p>
</div><p><strong>Gael Forterre</strong>, Chief Commercial Officer, Volition commented:</p>
<div class="lb-trans"><p><strong>蓋爾·福特爾，</strong> Volition 首席商業官評論道：</p>
</div><p>&#34;This represents a tremendous commercial opportunity for Volition:</p>
<div class="lb-trans"><p>&#34;這代表了 Volition 的巨大商業機會：</p>
</div><ul>
<li>the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment; and</li>
<li>we plan to generate ongoing revenue in this large and growing market where our technology meets an unmet need.</li>
</ul>
<div class="lb-trans"><ul>
<li>本研究在同行評審期刊上的發表預計將解鎖 500 萬美元的合同里程碑付款；並且</li>
<li>我們計劃在這個龐大且快速增長的市場中產生持續的收入，我們的技術滿足了未滿足的需求。</li>
</ul>
</div><p>&#34;Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.</p>
<div class="lb-trans"><p>&#34;我們的使命是使癌症篩查成為每隻寵物年度健康檢查的常規部分，在成功國際推廣我們的犬癌症檢測後，我們現在已經證明我們的技術對貓也有效。</p>
</div><p>&#34;We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our distribution networks including reference laboratories and point-of-care platforms.</p>
<div class="lb-trans"><p>&#34;我們期待完成產品開發，並通過我們的分銷網絡（包括參考實驗室和即時檢測平台）使 Nu.Q® Vet Feline 測試可用。</p>
</div><p>&#34;The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space.&#34;</p>
<div class="lb-trans"><p>&#34;Nu.Q® Vet Canine 測試已經在 20 多個國家可用，我們相信增加一個貓的等效測試可能會使我們在伴侶動物領域的總可尋址市場翻倍。&#34;</p>
</div><p>The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:</p>
<div class="lb-trans"><p>Nu.Q® Vet Feline 測試切入了一個重要的、快速增長的市場：</p>
</div><ul>
<li><strong>Large Population:</strong> There are approximately <strong>73.8 million pet cats in the United States</strong> alone6.</li>
<li><strong>High Risk:</strong> It is estimated that approximately <strong>1 in 5 cats</strong> will develop cancer in their lifetime7. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.</li>
<li><strong>The &#34;Senior&#34; Segment:</strong> Over <strong>25% of U.S. cats</strong> are considered seniors (aged 8+) 8, representing a recurring annual screening opportunity for over 18 million pets in the U.S.6,8</li>
<li><strong>Market Growth:</strong> The North American veterinary oncology market is projected to reach <strong>$1.77 billion by 2025</strong>, with the feline segment expected to grow at a faster Compound Annual Growth Rate than the canine segment due to increasing owner awareness and a growing focus on feline-specific treatments&#34;9.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>龐大的人口：</strong> 美國僅有約 <strong>7380 萬隻寵物貓</strong>。</li>
<li><strong>高風險：</strong> 估計約 <strong>五分之一的貓</strong> 在其一生中會患上癌症。貓淋巴瘤是該物種中最常見的癌症，是 Nu.Q®檢測的主要目標。</li>
<li><strong>“老年” 羣體：</strong> 超過 <strong>25% 的美國貓</strong> 被認為是老年貓（年齡 8 歲以上），這為美國超過 1800 萬隻寵物提供了每年定期篩查的機會。</li>
<li><strong>市場增長：</strong> 北美獸醫腫瘤學市場預計到 2025 年將達到 <strong>17.7 億美元</strong>，其中貓的細分市場預計將以比犬類細分市場更快的複合年增長率增長，原因是主人意識的提高和對貓特定治療的關注增加。&#34;</li>
</ul>
</div><p>The paper should be available on a preprint service in the coming days.</p>
<div class="lb-trans"><p>該論文將在接下來的幾天內在預印本服務上發佈。</p>
</div><ol>
<li>Data on File</li>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.</li>
<li>H. M. Wilson‑Robles et al, BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8</li>
<li>C. Dolan et al, BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-x</li>
<li>H. M. Wilson‑Robles et al, BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6</li>
<li><em>AVMA Pet Ownership Sourcebook</em> <em>(2025)</em> &amp; <em>APPA National Pet Owners Survey (2025)</em></li>
<li>Can Cats Get Cancer? Understanding Feline Cancers Like Lymphoma &amp; SCC. Imprimed</li>
<li>Data on file, Volition TAM model</li>
<li>Towards Healthcare: Veterinary Oncology Market Insights (October 2025)</li>
</ol>
<div class="lb-trans"><ol>
<li>數據存檔</li>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 第 6 版. Elsevier Health Sciences; 2019。</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8</li>
<li>C. Dolan 等，BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-x</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6</li>
<li><em>AVMA 寵物擁有源書</em> <em>(2025)</em> 6 <em>APPA 全國寵物主人調查 (2025)</em></li>
<li>貓會得癌症嗎？瞭解貓淋巴瘤和 SCC 等貓癌症。Imprimed</li>
<li>數據存檔，Volition TAM 模型</li>
<li>面向醫療保健：獸醫腫瘤學市場洞察（2025 年 10 月）</li>
</ol>
</div><p><strong>About Volition</strong></p>
<div class="lb-trans"><p><strong>關於 Volition</strong></p>
</div><p>About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.</p>
<div class="lb-trans"><p>關於 Volition：Volition 是一家專注於推進表觀遺傳學科學的跨國公司。Volition 致力於通過早期檢測以及疾病和治療監測來拯救生命並改善人類和動物在重大疾病中的預後。</p>
</div><p>Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.</p>
<div class="lb-trans"><p>通過其子公司，Volition 正在開發和商業化簡單、易用、經濟的血液檢測，以幫助檢測和監測一系列疾病，包括一些癌症和與 NETosis 相關的疾病，如膿毒症。早期檢測和監測不僅有潛力延長患者的生命，還能改善他們的生活質量。</p>
</div><p>Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.</p>
<div class="lb-trans"><p>Volition 的研究和開發活動集中在比利時，在美國設有創新實驗室和辦公室，並在倫敦設有辦公室。</p>
</div><p>The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.</p>
<div class="lb-trans"><p>Volition 網站上的內容不被視為本文件的一部分，也不應被視為本文件的一部分。該網站地址僅作為非活動文本引用包含在本文件中。</p>
</div><p><strong>Media Enquiries:</strong> Louise Batchelor, Volition, [email protected], +44 (0) 7557 774620</p>
<div class="lb-trans"><p><strong>媒體諮詢：</strong> Louise Batchelor, Volition, [email protected], +44 (0) 7557 774620</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港聲明</strong></p>
</div><p>Statements in this press release or associated video or link may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities, milestone payments and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.</p>
<div class="lb-trans"><p>本新聞稿或相關視頻或鏈接中的聲明可能是根據《1933 年證券法》第 27A 條和《1934 年證券交易法》第 21E 條的定義的 “前瞻性聲明”，涉及可能導致實際結果與前瞻性聲明中預期或預測的結果存在重大差異的風險和不確定性。諸如 “預計”、“預期”、“打算”、“計劃”、“目標”、“旨在”、“目標”、“相信”、“尋求”、“估計”、“優化”、“潛在”、“目標”、“建議”、“可能”、“將”、“應該”、“或許”、“會” 等類似表達識別前瞻性聲明。這些前瞻性聲明涉及的主題包括，Volition 對收入機會、里程碑付款和增長的預期，Volition 基於血液的診斷、預後和疾病監測測試的有效性和可用性，Volition 開發和成功商業化這些測試平台以早期檢測癌症和其他疾病的能力，以及作為這些疾病的診斷、預後或疾病監測工具的能力，Volition 對未來出版物的預期，Volition 在與第三方為其產品達成許可和/或分銷協議方面的成功，以及 Volition 對這些協議條款的預期。由於眾多風險和不確定性，Volition 的實際結果可能與這些前瞻性聲明中所指示的結果存在重大差異，包括但不限於測試有效性研究的結果。例如，如果 Volition 未能開發和商業化診斷、預後或疾病監測產品，可能無法執行其運營計劃。其他風險和不確定性包括 Volition 未能獲得必要的監管許可或批准以分銷和營銷未來產品；市場未能接受 Volition 開發管道中的產品或 Volition 可能開發的任何其他診斷、預後或疾病監測產品；Volition 未能獲得足夠的知識產權保護；Volition 將面臨激烈的競爭，且由於診斷和疾病監測市場的高度競爭性及其快速的技術變革，Volition 計劃中的產品可能會變得過時；國內和國際經濟的下滑；以及其他風險，包括在 Volition 最近的 10-K 表格年度報告和 10-Q 表格季度報告中識別的風險，以及 Volition 向證券交易委員會提交的其他文件。這些聲明基於當前的預期、估計和關於 Volition 業務的預測，部分基於管理層做出的假設。這些聲明並不保證未來的表現，並涉及難以預測的風險、不確定性和假設。前瞻性聲明是在本發佈之日作出的，除法律要求外，Volition 不承擔更新其前瞻性聲明以反映未來事件或情況的義務。</p>
</div><p>rNuQ™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United States of America.</p>
<div class="lb-trans"><p>rNuQ™、Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的標誌是 VolitionRx Limited 及其子公司的商標和/或服務標誌。本新聞稿或相關視頻或鏈接中提到的所有其他商標、服務標誌和商號均為其各自所有者的財產。此外，除非另有説明，所有提及的 “$” 均指美國法定貨幣。</p>
</div><p>Image - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg</p>
<div class="lb-trans"><p>圖片 - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg</p>
</div><p>SOURCE VolitionRx Limited</p>
<div class="lb-trans"><p>來源：VolitionRx Limited</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA2Jk5ld3NJdGVtSWQ9TE41MjU5NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDYwODE3UFJfTkVXU19VU1BSX19fX19MTjUyNTk3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN52597&amp;Transmission_Id=202605060817PR_NEWS_USPR_____LN52597&amp;DateId=20260506"/></p>

08:17 ET VolitionRx 宣佈提交關於 Nu.Q®獸醫癌症測試在貓中應用的手稿